<DOC>
	<DOC>NCT02016560</DOC>
	<brief_summary>This is a cross-sectional and longitudinal study that will evaluate imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects.</brief_summary>
	<brief_title>Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Exploratory Cognitively Healthy Subjects ≥ 20 to ≤ 40 years of age OR ≥ 50 years of age Minimental state examination (MMSE) ≥ 29 No significant history of cognitive impairment Exploratory MCI Subjects ≥ 50 years of age MMSE ≥ 24 Have MCI consistent with National Institute on AgingAlzheimer's Association (NIAAA) working group's diagnostic guidelines for AD Have a study partner that can report on subject's activities of daily living Exploratory AD Subjects ≥ 50 years of age MMSE &gt; 10 Have possible or probable AD based on the NIAAA working group's diagnostic guidelines for AD Have a study partner that can report on subject's activities of daily living Confirmatory Subjects ≥ 50 years of age MMSE ≥ 20 and ≤ 27 Cognitively impaired subjects with either MCI or dementia with a suspected neurodegenerative cause Have a study partner that can report on subject's activities of daily living Current clinically significant psychiatric disease Evidence of structural brain abnormalities History of moderate or severe traumatic brain injury Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer History of alcohol or substance abuse or dependence Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception Have received or participated in a trial with investigational medications in the past 30 days Have had a nonstudy related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>